Vunakizumab | m-entrepreneurship.com

Product Name :
Vunakizumab

Search keywords :
Vunakizumab

drugId :
null

Target Vo:
Interleukin 17A

Target Vo Short Name :
IL17A

Moa_Name:
Interleukin 17A inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Jiangsu Hengrui Medicine Co Ltd

Active Company_Name :
Jiangsu Hengrui Medicine Co Ltd

Active Indication_Name:
Spondylitis, Ankylosing

In Active Indication_Name:
Autoimmune Diseases

Termination Status :

China Termination Status :

Highest Status:
NDA/BLA

China Highest Status:
NDA/BLA

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
ATG10 Antibody
Bcl2 Antibody
NMDAR2A Antibody: NMDAR2A Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 165 kDa, targeting to NMDAR2A. It can be used for WB,IHC-P,IF assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts